tiprankstipranks
Trending News
More News >
D.Western Therapeutics Institute, Inc. (JP:4576)
:4576
Advertisement

D.Western Therapeutics Institute (4576) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4576

D.Western Therapeutics Institute

(Frankfurt:4576)

Rating:42Neutral
Price Target:
¥114.00
▼(-2.56%Downside)
The most significant factor impacting the score is the company's poor financial performance, with ongoing losses and cash flow issues raising concerns about sustainability without external financing. Technical analysis suggests some potential for recovery but lacks strong momentum. The stock's valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors combine to produce a low overall stock score.

D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)

D.Western Therapeutics Institute Business Overview & Revenue Model

Company DescriptionD.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research, development, and commercialization of pharmaceutical products. The company primarily focuses on the development of innovative drugs and therapeutic solutions targeting various medical conditions. Its core areas include ophthalmology and other therapeutic fields where it aims to address unmet medical needs.
How the Company Makes MoneyD.Western Therapeutics Institute generates revenue through the development and commercialization of its pharmaceutical products. The company earns money by licensing its drug compounds to larger pharmaceutical companies, which may include milestone payments and royalties based on sales. Additionally, it may engage in collaborative research and development partnerships with other companies in the pharmaceutical industry, which can provide further revenue streams through shared resources and expertise.

D.Western Therapeutics Institute Financial Statement Overview

Summary
D.Western Therapeutics Institute, Inc. faces significant financial challenges. While the gross profit margin is strong, negative EBIT and net profit margins, along with inconsistent revenue growth, indicate severe operational difficulties. Cash flow issues, including negative operating and free cash flows, suggest potential liquidity threats and unsustainable reliance on external financing.
Income Statement
30
Negative
The company's income statement reveals significant challenges. The gross profit margin remains healthy, but both EBIT and net profit margins are negative, reflecting substantial operating losses. Revenue growth has been inconsistent, with a decline in recent years, indicating potential market or operational difficulties.
Balance Sheet
40
Negative
The balance sheet shows a moderate financial position. The debt-to-equity ratio is reasonable, suggesting controlled leverage. However, the return on equity is negative due to persistent net losses. The equity ratio is satisfactory, indicating a stable asset base relative to liabilities.
Cash Flow
25
Negative
Cash flow analysis highlights severe issues, with negative operating and free cash flows indicating cash burn and potential liquidity concerns. The free cash flow to net income ratio is unfavorable, underlining inefficiencies in converting profits into cash. Financing activities have been used to supplement operations, which may not be sustainable long-term.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue471.58M428.36M448.10M414.42M355.59M
Gross Profit424.74M391.70M420.53M394.32M338.57M
EBITDA-1.23B-775.59M-390.75M-110.03M-240.64M
Net Income-1.29B-812.41M-429.69M-149.00M-276.10M
Balance Sheet
Total Assets1.67B2.37B2.96B2.46B2.74B
Cash, Cash Equivalents and Short-Term Investments1.13B1.87B2.33B1.93B2.31B
Total Debt797.98M885.12M967.69M340.00M460.00M
Total Liabilities935.58M1.09B1.08B427.72M573.81M
Stockholders Equity733.87M1.28B1.86B2.01B2.16B
Cash Flow
Free Cash Flow-1.31B-601.76M-364.58M-179.21M-221.41M
Operating Cash Flow-1.30B-586.82M-354.77M-176.31M-216.28M
Investing Cash Flow-10.01M-15.25M-139.89M-111.15M-13.46M
Financing Cash Flow567.63M134.47M867.30M-104.46M1.00B

D.Western Therapeutics Institute Technical Analysis

Technical Analysis Sentiment
Negative
Last Price117.00
Price Trends
50DMA
123.04
Negative
100DMA
116.11
Positive
200DMA
114.88
Positive
Market Momentum
MACD
-0.28
Positive
RSI
41.19
Neutral
STOCH
8.99
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 117 is below the 20-day moving average (MA) of 124.95, below the 50-day MA of 123.04, and above the 200-day MA of 114.88, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 41.19 is Neutral, neither overbought nor oversold. The STOCH value of 8.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.

D.Western Therapeutics Institute Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
¥4.74B19.07
18.71%33.40%
65
Neutral
¥354.70B11.38-2.99%2.49%11.76%-10.21%
54
Neutral
¥3.50B
12.66%24.73%
47
Neutral
¥8.83B-148.36%22.93%47.73%
42
Neutral
¥5.35B-113.58%4.59%9.71%
38
Underperform
¥4.46B
1056.04%21.63%
28
Underperform
¥8.64B
-11.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4576
D.Western Therapeutics Institute
117.00
27.00
30.00%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
510.00
10.00
2.00%
JP:4598
Delta-Fly Pharma, Inc.
715.00
109.00
17.99%
JP:4881
FunPep Company Limited
109.00
-59.00
-35.12%
JP:4884
Kringle Pharma, Inc.
512.00
-473.00
-48.02%
JP:4564
OncoTherapy Science
29.00
-14.00
-32.56%

D.Western Therapeutics Institute Corporate Events

D. Western Therapeutics Institute Unveils New Pipeline for Ocular Diseases
Jul 15, 2025

D. Western Therapeutics Institute has announced the development of ‘H-1129’ as a new pipeline candidate for treating ocular surface diseases related to immune disorders, such as keratoconjunctival diseases. This strategic move aims to leverage the company’s existing intellectual property and expertise in kinase inhibitors, following the discontinuation of its development as a glaucoma treatment. The company plans to initiate clinical trials in fiscal year 2026, with no immediate impact on the current earnings forecast, although future revisions may be announced if necessary.

D. Western Therapeutics Expands Glaucoma Treatment to Thailand
Jul 10, 2025

D. Western Therapeutics Institute, Inc. has announced the launch of its glaucoma and ocular hypertension treatment, ‘GLA-ALPHA® Combination Ophthalmic Solution,’ in Thailand through its partner Kowa Co., Ltd. This marks the first international commercialization of the product, which combines ripasudil hydrochloride hydrate and brimonidine tartrate, offering a novel treatment option with a different action site compared to existing solutions. The launch is expected to enhance treatment adherence among patients requiring multiple medications, although the immediate financial impact on DWTI’s fiscal year is projected to be minimal. The company anticipates further overseas expansion following the steady growth of its products in Japan and Thailand.

D.Western Therapeutics Partners with Chordia for Ophthalmic Drug Development
Jul 8, 2025

D.Western Therapeutics Institute has announced a joint research agreement with Chordia Therapeutics to develop therapeutic agents for ophthalmic diseases using a compound from Chordia’s oncology pipeline. This collaboration leverages both companies’ expertise and resources, with Chordia providing research materials and D.Western conducting efficacy studies. While this partnership will not affect the current fiscal year’s earnings forecast, it is expected to expand D.Western’s ophthalmology pipeline in the medium to long term.

DWTI’s GLA-ALPHA Ophthalmic Solution Gains Approval in Singapore
Jun 30, 2025

D.Western Therapeutics Institute announced that its partner, Kowa Co., Ltd., received marketing approval in Singapore for the GLA-ALPHA Combination Ophthalmic Solution, a novel treatment for glaucoma and ocular hypertension. This approval marks a significant step in DWTI’s international expansion strategy, as the product is already marketed in Japan and Thailand. While the approval does not immediately impact DWTI’s financial results, it is expected to enhance long-term earnings through royalties and improved market positioning.

D. Western Therapeutics Completes Dosing in Global Phase III Trial for Eye Treatment
Jun 20, 2025

D. Western Therapeutics Institute announced the completion of subject dosing in the global Phase III clinical trial of ‘K-321,’ an ophthalmic solution for treating Fuchs endothelial corneal dystrophy. This milestone marks a significant step in evaluating the efficacy and safety of K-321, which is administered post-Descemet’s membrane stripping surgery. The trial, conducted in multiple regions including the US and Europe, is now in the follow-up observation phase, with results expected by March 2026. The development of K-321 is crucial as it offers a potential new treatment option for a condition that currently relies heavily on corneal transplantation. Despite this progress, the company stated that there will be no change to the earnings forecast for the fiscal year ending December 2025.

D.Western Therapeutics Institute Reports First Quarter Financial Results
May 15, 2025

D.Western Therapeutics Institute reported a decrease in net sales for the first quarter of 2025, with a 7.7% decline compared to the previous year. Despite the reduction in losses, the company still faces challenges with negative operating and ordinary profits, indicating ongoing financial difficulties.

D.Western Therapeutics and RaQualia Pharma Achieve Positive Results in Eye Disease Drug Research
May 15, 2025

D.Western Therapeutics Institute, in collaboration with RaQualia Pharma, has achieved positive results in their joint research aimed at developing new drug candidates for eye diseases. This research, which began in December 2022, confirmed favorable pharmacological effects in animal models and is expected to contribute to the medium-to-long-term expansion of DWTI’s ophthalmology pipeline, though it will not impact the current fiscal year’s earnings forecast.

D.Western Therapeutics Extends Cataract Research Partnership
May 15, 2025

D.Western Therapeutics Institute, Inc. has extended its joint research agreement with the University of Fukui to develop novel therapeutic and preventive drugs for cataracts. This collaboration aims to create an eye drop formulation as an alternative to cataract surgery, offering a broader range of treatment options and reducing the burden on patients. The extension of this agreement signifies the company’s commitment to advancing ophthalmological research, although it will not affect the earnings forecast for the fiscal year ending December 2025.

D.Western Therapeutics Secures Macau Patent for Diagnostic Agent
May 14, 2025

D.Western Therapeutics Institute’s subsidiary, Japan Innovative Therapeutics, Inc., has secured a patent in Macau for a diagnostic agent targeting retinopathy of prematurity and related conditions. This patent, which strengthens the company’s intellectual property portfolio, is expected to enhance corporate value over the medium to long term despite having no immediate impact on the fiscal earnings forecast.

DWTI Showcases Promising H-1337 Trial Results at ARVO 2025
May 7, 2025

D. Western Therapeutics Institute announced the presentation of late Phase II clinical trial results for their drug H-1337 at the ARVO 2025 conference, highlighting its significant intraocular pressure-lowering effects and tolerability for treating open-angle glaucoma and ocular hypertension. This presentation is expected to enhance the company’s international profile and support its licensing activities, although it will not affect the earnings forecast for the fiscal year ending December 2025.

D.Western Therapeutics Partners with Mie University for Drug Development
Apr 30, 2025

D.Western Therapeutics Institute, Inc. has entered a joint research agreement with Mie University to develop new drugs for lifestyle-related diseases using their low-molecular-weight compounds. This collaboration will leverage zebrafish models for efficient drug screening, potentially enhancing the company’s capabilities and impact in the pharmaceutical industry, though it will not affect the current fiscal year’s earnings forecast.

D.Western Therapeutics Institute Initiates Joint Research for Advanced Eye Disease Treatments
Apr 28, 2025

D.Western Therapeutics Institute, Inc. has entered a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop next-generation drug formulations for eye diseases. This collaboration aims to address the increasing patient needs for effective treatments by enhancing drug efficacy and intraocular penetration, without impacting the company’s earnings forecast for the fiscal year ending December 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025